• January 5, 2016Chairman’s Annual Update
Agenus - mark

At Agenus, we believe the best path for treating disease is through activating our own body’s natural mechanisms.

That’s why for 20 years, we’ve focused on building technologies and a product pipeline aimed at treating cancer and infectious disease by helping the body’s immune system target diseased cells with precision.

  • 19 May 2016

    Agenus Appoints Ulf Wiinberg to Board of Directors
    Read More


  • 28 Apr 2016

    Agenus Reports First Quarter 2016 Financial Results and Operational Progress
    Read More


  • 27 Apr 2016

    Agenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors
    Read More


  • 21 Apr 2016

    Agenus to Report First Quarter 2016 Financial Results on April 28, 2016; Conference Call to Follow
    Read More


  • 18 Apr 2016

    Agenus Presents Posters on Checkpoint Antibody Product Candidates at the American Association for Cancer Research (AACR) 2016 Annual Meeting
    Read More


  • 30 Mar 2016

    Agenus to Participate at Three Upcoming Oncology Conferences
    Read More